Multiple Myeloma

FDA Grants Fast Track Designation to Inobrodib in R/R Multiple Myeloma

Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.

$Inobrodib is under investigation as a treatment for patients with relapsed/refractory multiple myeloma and other hematologic malignancies in a phase 1/2a trial.$

MonumenTAL-1: Data Updates of Non-BCMA Bispecifics in MM

Inobrodib is under investigation as a treatment for patients with relapsed/refractory multiple myeloma and other hematologic malignancies in a phase 1/2a trial.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

MagnetisMM-1: Data Updates of Anti-BCMA Bispecifics in MM

Shared insight from Rafael Fonseca, MD, on data from MonumenTAL-1 and the use of talquetamab therapy in patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM

Expert perspectives from Joselle Cook, MBBS, on use of elranatamab in relapsed/refractory multiple myeloma based on data from the MagnetisMM-1 trial.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM

David Witt, MD, details the design and outcomes of the GRIFFIN study in newly diagnosed multiple myeloma.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Natalia Neparidze, MD, reviews the available induction treatment options for patients with newly diagnosed multiple myeloma (NDMM).

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

Bispecifics in Relapsed/Refractory Multiple Myeloma: Adverse Event Management

Experts in multiple myeloma management review the role of CAR T-cell therapy in patients with relapsed/refractory disease.

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

Cilta-Cel Yields Long-Term Efficacy in Pretreated R/R Multiple Myeloma

Focused discussion on mitigating and managing the adverse event profiles of bispecifics in relapsed/refractory multiple myeloma.

Teclistamab Combo Yields Responses, No New Toxicity in R/R Multiple Myeloma

June 11th 2023

A single infusion of ciltacabtagene autoleucel produces a manageable safety profile among patients with relapsed/refractory multiple myeloma in the phase 1b/2 CARTITUDE-1 study.

Daratumumab Combo Yields Responses in Pretreated R/R Multiple Myeloma

June 10th 2023

Findings from the phase 1b RedirecTT-1 study may support initiating larger studies evaluating teclistamab plus talquetamab for patients with relapsed or refractory multiple myeloma.

$Results from the phase 2 DARIA trial found an improved overall response rate in patients given daratumumab, ixazomib, and dexamethasone with relapsed/refractory multiple myeloma who were previously treated with lenalidomide.$

Ariana Pelosci

Triplet Induction Therapy in Patients With Transplant-Eligible NDMM

Results from the phase 2 DARIA trial found an improved overall response rate in patients given daratumumab, ixazomib, and dexamethasone with relapsed/refractory multiple myeloma who were previously treated with lenalidomide.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

MAIA Trial: DRd in Patients with Newly Diagnosed MM

Focused discussion on the historical use of triplet regimens as induction therapy in transplant-eligible newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Overview on Risk Stratification in Multiple Myeloma

Insights gleaned from the MAIA trial, which researched daratumumab, lenalidomide, and dexamethasone in patients with newly diagnosed MM.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Thomas Atkinson, MD;Ernest C. Quintin, MD

Patient Profile 2: A 74-Year-Old with Transplant-Ineligible NDMM

Opening its discussion on the management of multiple myeloma, a panel of experts from Ochsner Health reviews risk stratification strategies via NCCN and mSMART guidelines.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma

Myeloma experts present the case of a 74-year-old with transplant-ineligible newly diagnosed MM and offer their initial impressions.

A Satellite Sessions program at the Yale Cancer Center discusses treatment paradigms and unmet needs in multiple myeloma as well as transplantation, bispecific T-cell engaging therapies, and the importance of collaborative decision-making in clinical practice.

Nicholas Wrigley

June 8th 2023

A Satellite Sessions program at the Yale Cancer Center discusses treatment paradigms and unmet needs in multiple myeloma as well as transplantation, bispecific T-cell engaging therapies, and the importance of collaborative decision-making in clinical practice.

Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 8th 2023

April Logue, APRN-CNP, shares her perspective on selecting between doublet and triplet regimens for patients with transplant-ineligible newly-diagnosed multiple myeloma.

Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 8th 2023

Naresh Bumma, MD, reviews updated data from the MAIA trial in transplant-ineligible newly-diagnosed multiple myeloma.

$FDA Accepts sBLA for Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com.$

FDA Accepts sBLA for Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment

Findings from the phase 3 CARTITUDE-4 study support the supplemental biologics license application for ciltacabtagene autoleucel in the treatment of relapsed/refractory multiple myeloma.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP

Treatment with Teclistamab Following Progression on CAR-T in R/R MM

The panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

The panel shares their experiences with the sequencing of BCMA-targeting therapies in MM, with particular focus on treatment of patients who progress on CAR T-cell therapy with teclistamab.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

MajesTEC-1: Data Updates of Anti-BCMA Bispecifics in MM

Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Case 4: A 77-Year-Old with MM Treated with Bispecifics and Develops Neutropenia

Expert Shaji Kumar, MD, spearheads a review of data from MajesTEC-1 and use of teclistamab therapy in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Overview of Treatment Options in Relapsed/Refractory Multiple Myeloma

An expert panel offers their initial impressions on the case of a 77-year-old with multiple myeloma treated with a BCMA bispecific antibody who develops neutropenia.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Managing Hypogammaglobulinemia Associated with Bispecifics in MM

Opening the panel’s discussion on multiple myeloma management, Rafael Fonseca, MD, reviews treatment options available to patients at early or late relapse.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Bispecific Antibodies in Development for the Treatment of R/R MM

A panel of experts on multiple myeloma discuss the use of IVIG in the management of hypogammaglobulinemia in patients treated with bispecific antibodies.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM

Dr Jack Khouri highlights recent data updates on other BCMA-targeting bispecific antibodies that are in clinical development in multiple myeloma.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Viral Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies

Dr Jeremy Larsen reviews data from the MonumenTAL-1 study investigating the CD3- and GPRC5D-targeting bispecific antibody talquetamab in relapsed/refractory multiple myeloma.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP